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Chronic Chagas Cardiomyopathy (CCM) is a unique form of cardiomyopathy compared to
other etiologies of heart failure. In CCM, risk prediction based on biomarkers has not been
well-studied. We assessed the prognostic value of a biomarker panel to predict a composite
outcome (CO), including the need for heart transplantation, use of left ventricular assist
devices, and mortality.
Methods
Prospective cohort study of 100 adults with different stages of CCM. Serum concentrations
of amino-terminal pro-B type natriuretic peptide (NT-proBNP), galectin-3 (Gal-3), neutrophil
gelatinase-associated lipocalin (NGAL), high sensitivity troponin T (hs-cTnT), soluble
(sST2), and cystatin-C (Cys-c) were measured. Survival analyses were performed using
Cox proportional hazard models.
Results
During a median follow-up of 52 months, the mortality rate was 20%, while the CO was
observed in 25% of the patients. Four biomarkers (NT-proBNP, hs-cTnT, sST2, and Cys-C)
were associated with the CO; concentrations of NT-proBNP and hs-cTnT were associated
with the highest AUC (85.1 and 85.8, respectively). Combining these two biomarkers above
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their selected cut-off values significantly increased risk for the CO (HR 3.18; 95%CI 1.31–
7.79). No events were reported in the patients in whom the two biomarkers were under the
cut-off values, and when both levels were above cut-off values, the CO was observed in
60.71%.
Conclusion
The combination of NT-proBNP and hs-TnT above their selected cut-off values is associ-
ated with a 3-fold increase in the risk of the composite outcome among CCM patients. The
use of cardiac biomarkers may improve prognostic evaluation of patients with CCM.
Background
Chagas Disease (CD), or American trypanosomiasis, is an infectious disease caused by the pro-
tozoan parasite Trypanosoma cruzi and currently affects approximately eight million people in
endemic countries in Central and South America [1]. Moreover, an estimated 300,000 infected
individuals live in the United States of America, and almost 100,000 live in the European
Union with this disease. Furthermore, the pooled prevalence of infection in Latin American
migrants is estimated to be around 4.2% [2–5]. Underdiagnoses of CD are frequent, estimated
at up to 95% in certain areas, highlighting the need for health professionals with experience in
this area [6]. The acute phase of this disease often goes under-recognized, as it is rarely severe;
nevertheless, 30% of infected individuals will develop a symptomatic chronic phase character-
ized by severe digestive or cardiac forms of the disease [7]. Chronic Chagas cardiomyopathy
(CCM) is the most common form of chronic disease; characterized by an extensive arrhyth-
mogenic and thrombogenic status, myocardial fibrosis, segmental wall motion abnormalities,
and ultimately a dilated cardiomyopathy with rapidly progressive heart failure, all of which
confer high morbidity and mortality [8].
Once a patient with CD develops cardiomyopathy, predicting risk for complications (such
as death or need for advanced support strategies including mechanical circulatory support or
cardiac transplantation) may be challenging. A relatively under-explored option for risk pre-
diction in CD cardiomyopathy is the use of biomarkers. Population-based studies have identi-
fied various biomarkers that may predict multiple outcomes in different pathogen-related
diseases [9]. However, the experience regarding biomarkers use in CD has shown that numer-
ous challenges still remain to allow optimal use and reliably estimate the risk of CCM progres-
sion [10, 11]. Moreover, while several serum biomarkers have been identified as having a
significant diagnostic and prognostic value in heart failure (HF) of other etiologies, few studies
have addressed their role in CCM, which, given its unique pathogenesis, warrants direct con-
firmation [12–14].
Previous work has suggested that multimodal biomarker assessment can be an important
tool to improve the assessment of the prognosis in this population [15, 16]. However, data are
scarce regarding the use of this strategy in patients with CD. In this context, we sought to eval-
uate the discriminative ability of a broad range of cardiac and renal biomarkers to assess the
risk of mortality and other relevant clinical outcomes in CCM patients.
Methods
Study population
This prospective cohort study was performed between July 2015 to January 2020 conducted in
the Heart Failure and Heart Transplant Clinic of Fundación Cardiovascular, in Floridablanca,
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Colombia. The research protocol of the study was approved by the Institutional Committee on
Research Ethics of the Fundación Cardiovascular de Colombia. Written consent was obtained
for all patients. Adult outpatients (> 18 years old) with a positive serological diagnosis of T.
cruzi infection (positive IgG antibodies) and echocardiographic (echo) or electrocardiographic
(ECG) abnormalities consistent with chronic Chagas cardiomyopathy (left anterior fascicular
block, right bundle branch block, atrioventricular blocks, ventricular premature beats, atrial
fibrillation or flutter, bradycardia�50 h/min or echocardiographic finding suggesting myo-
cardial alterations as evaluated by a cardiologist) were included. We enrolled patients across all
the severity stages, including also individuals with implantable devices and refractory heart
failure. The study sample was obtained from the CCM patients attending their follow-up eval-
uations; the first 100 individuals who fulfilled the inclusion criteria were enrolled. We excluded
individuals with diabetes mellitus, coronary heart disease history, mitral stenosis, or uncon-
trolled hypertension. The Institutional Committee on Research Ethics approved the research
protocol of the study. All patients provided written informed consent for their participation in
the study.
Data collection
Information regarding socioeconomic status, lifestyle factors, and medication use was
recorded. Body-mass index, left ventricular ejection fraction (LVEF) calculated by Simpson’s
rule from four-chambers view, global longitudinal strain by speckle tracking (GLS), and esti-
mated glomerular filtration rate (eGFR) were also measured. Finally, fasting serum samples
were collected from each individual for the assessment of the six biomarkers. High sensitivity
troponin T (hs-cTnT) was quantified with a 5th generation assay on an automated platform
(ECLIA Elecsys 2010 analyzer, Roche Diagnostics, Germany). Galectin-3 (Gal-3) was assessed
by using a quantitative method, specifically an ELFA (enzyme-linked fluorescent assay) tech-
nique (VIDAS, Biomerieux, Marcy l’Étoile, France). Amino-terminal pro-B type natriuretic
peptide (NT-proBNP) levels were measured using the electrochemiluminescence method
(Roche Diagnostics GmbH, Mannheim, Germany). The Alere Triage1 NGAL test was used
to assess Neutrophil Gelatinase-Associated Lipocalin (NGAL). Soluble ST2 (sST2) was mea-
sured from banked serum by Critical Diagnostics Presage™ sST2 assay kit via enzyme-linked
immunosorbant assay (ELISA). Finally, Cystatin c (Cys-c) was quantified by an immunologic
turbid metric assay (Tina-quant Cystatin C cobas1).
Study outcomes and follow-up
The primary outcome of this study was a composite endpoint of cardiovascular mortality,
heart transplant, and left ventricular assistance device (LVAD) implantation, while the second-
ary outcome was cardiovascular mortality. After the baseline information collection, a tele-
phone follow-up and review of the clinical records of each patient was performed according to
a standardized protocol. Investigators contacted the patients once a month during the first six
months after the initial evaluation; after that, patients were called every six months. During the
telephone interview, a standardized checklist of questions aimed to identify the mentioned
outcomes was used.
Statistical analysis
Categorical variables were presented as numbers and proportions, while continuous variables
were reported as medians and interquartile ranges. Survival analyses were performed using the
Kaplan-Meier method, life table, and Cox proportional hazard models. We considered the
time to event for the CO as the number of days from enrollment to the study until the first of
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the components of this outcome was reached. To identify the variables that were indepen-
dently predictive of mortality, univariate and multivariate analyses using Cox’s proportional
regression model were performed. Due to the sample size, only age and left ventricle ejection
fraction (LVEF) were included in the model, hazard ratios with its 95% confidence interval
were calculated. We quantified the discriminatory ability of the biomarkers using the Harrell’s
C statistic and the area under the receiver operating characteristic curve (AUC-ROC). The
Youden index was used to identify the best cut-off level for each biomarker(16). A p-value
<0.05 was considered statistically significant for all tests. All analyses were performed using
Statistical Package STATA version 15 (Station College, Texas USA).
Results
Population characteristics
One hundred individuals were included (55% males with a median age of 62 years [IQR 53–
70]. 25% of the patients had a normal LVEF, but only 10% of the included patients had a nor-
mal global longitudinal strain (GLS) value. As expected, most of the biomarker measurements
were elevated. Median NT-proBNP was 704 (IQR 170–2846) pg/mL, hs-cTnT: 11.7 (IQR 5.6–
22.6) ng/L, sST2: 24.7 (IQR 20.1–31.9) ng/mL, Gal-3 had a median value of 14.2 (IQR 11.5–
18.3) ng/mL, while median Cys-C and NGAL values were 1.1 (IQR 0.9–1.4) mg/L and 96.5
(IQR 69.0–145.5) ng/mL, respectively. Table 1 shows a summary of the included population
characteristics by the CO.
Incidence and rate of outcomes
After a mean of 52 months (Q1 = 42; Q3 = 54) of follow-up, there were 25 events (20 deaths,
four transplants, and one LVAD implantation). The mortality in this cohort was 20% (95% CI
13.2% - 29.2%), with a mortality rate of 0.15 per 1000 person-years (95% CI 0.09–0.23). The
overall incidence of this composite outcome was 25% (95% CI 16.8–34.6%), with a rate of 0.18
per 1000 person-years (95% CI 0.12–0.28). We must highlight that we did not have any loss to
follow-up during this period.
Biomarkers as predictors of adverse outcomes in CCM
All biomarkers were significantly associated with the CO (Fig 1); nevertheless, in age and
LVEF adjusted models, log-transformed continuous concentrations of each biomarker were
associated with the CO, except for NGAL and Galectin-3 (Table 2). Considering each bio-
marker dichotomously, only two evaluated biomarkers (ST2 and hs-cTnT) were significantly
associated with the composite outcome (Table 2).
To analyze the potential additive value of combining sST2 and NT-proBNP measurements
for predicting the composite outcome, the sample was divided into four groups based on these
biomarkers cut-off points. There were only two (3.92%) deaths, HT or LVAD implantations in
the patients with levels of both sST2 below 35 ng/mL and NT-proBNP under 1000 pg/ml; in
contrast, the composite outcome was present in 81.25% (n = 13) of those with both these two
biomarkers over the selected cut-off values, conferring a significantly higher risk when com-
pared to those patients without sST2 or NT-proBNP elevations (HR 11.84; 95% CI 1.97–70.85)
(Fig 2). In addition, the AUC for this combination was significantly higher than the ones for
dichotomic sST2 (p = 0.001) and NT-proBNP (p = 0.038). Furthermore, considering that sST2
is not readily available in most clinical contexts, we analyzed the value of combined NT-
proBNP and hs-TnT analysis for predicting the composite outcome (Fig 3). The results were
similar to the ST2 and NT-proBNP combination, with no cases of the CO in the group of
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patients with NT-proBNP <1000 pg/ml and Hs-TnT <15 ng/ml, while in the group of indi-
viduals with NT-proBNP >1000 pg/ml and Hs-TnT >15 ng/ml almost 61% (n = 17) had one
of the events of the CO (Fig 3). Furthermore, this group’s CO risk compared to those without
hs-TnT or NT-proBNP alterations over the cut-offs was significantly higher (HR 3.18; 95%CI
1.31–7.79). The AUC value for the combined NT-proBNP and Hs-cTnT was also significantly
Table 1. Baseline characteristics the evaluated chronic Chagas cardiomyopathy patients (n = 100).
Variable Composite Outcome p-value
No (%) Yes (%)
Sex
Female 34 (45.33) 11 (44) 0.908
Male 41 (54.67) 14 (56)
Age (years) 61 (53–67) 66 (56–74) 0.112
Area of Residence
Urban 56 (74.67) 20 (80) 0.589
Rural 19 (25.33) 5 (20)
BMI (kg/m2) 26.4 (23.4–28.6) 22.8 (19.6–28.6) <0.001
NYHA 0.004
I 27 (36) 5 (20)
II 36 (48) 7 (28)
III 11 (14.67) 12 (48)
IV 1 (1.33) 1 (4)
LVEF (%) 49 (37–60) 25 (18–30) <0.001
GLS (%) -14.5 (-19.5; -9.3) -7.2 (-11.1; -2.9) <0.001
Pharmacotherapy
ACEI or ARB 51 (68) 20 (80) 0.252
Beta-blockers 53 (70.67) 24 (96) 0.009
Aldosterone Antagonists 38 (50.67) 20 (80) 0.010
Diuretics 28 (37.33) 22 (88) <0.001
Amiodarone 21 (28.57) 6 (25) 0.771
Digitalis 8 (10.67) 9 (36) 0.003
Ivabradine 1 (1.33) 2 (8) 0.091
Antiplatelet agents 26 (34.67) 3 (12) 0.031
Anticoagulants 23 (30.67) 14 (56) 0.023
Biomarkers
NT-proBNP (pg/mL) 352 (89–1423) 5583 (1566–8703) <0.001
hs-cTnT (ng/mL) 9.2 (4.04–15.97) 30 (17.00–69.32) <0.001
NGAL (ng/mL) 83 (64–112) 147 (108–254) <0.001
Cys-C (mg/L) 1.05 (0.87–1.26) 1.54 (1.22–1.89) <0.001
Creatinine (mg/dL) 1.08 (0.92–1.24) 1.2 (1.03–1.54) 0.046
Galectin-3 (ng/mL) 13.7 (10.8–16.2) 19.6 (14.6–24.1) <0.001
(s)ST2 (ng/mL) 22.9 (18.7–28.6) 37.4 (26.7–59.9) <0.001
GFR (ml/min/1.73m2) 61 (55–61) 56 (43–61) 0.037
This table contains % for categorical variables and median (first and third quartile) for continuous variables.
Abbreviations: BMI: Body Mass Index; NYHA: New York Heart Association; LVEF: Left Ventricle Ejection Fraction;
GLS: Global Longitudinal Strain; ACEI: Angiotensin-Converting Enzyme Inhibitor; ARB: Angiotensin Receptor
Blocker; NTproBNP: N-terminal brain natriuretic propeptide; Gal-3: Galectin-3 (Gal-3); NGAL: Neutrophil
gelatinase-associated lipocalin (NGAL); sST2: Soluble ST2; Cys-c: Cystatin-C; Hs-cTnT: High sensitivity cardiac
troponin T.
https://doi.org/10.1371/journal.pone.0258622.t001
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Fig 1. Kaplan Meier survival analyses for the composite outcome stratified by biomarker results above and below selected cut-off values. Survival by results of (A)
N-terminal brain natriuretic peptide (NTproBNP); (B) High sensitivity troponin T (Hs-cTnT); (C) sST2; (D) Galectin-3; (E) Cystatin C (Cys-C); (F) Neutrophil
Gelatinase-Associated Lipocalin (NGAL).
https://doi.org/10.1371/journal.pone.0258622.g001
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higher than the one of the dichotomic NT-proBNP (p = 0.037) but was not different from the
one of the dichotomic Hs-cTnT (p = 0.064). Similar results were observed when performing a
sensitivity analysis focusing on mortality as the outcome (S1 Table). Finally, the combined
analysis using the three biomarkers over their selected cut-off values revealed an 11-fold
increased risk of the CO (HR 11.25; 95% CI 1.94–65.14) (Fig 4).
Discussion
This prospective cohort study represents the first study to extensively analyze the prognostic
value of a series of cardiorenal biomarkers in CCM. Five serum biomarkers (NT-proBNP, hs-
cTnT, sST2, Gal-3, and Cys-C) were independently associated with mortality and the CO.
Additionally, NT-proBNP and hs-TnT showed the highest prognostic value in predicting the
CO in this population. Of note, Hs-cTnT had a similar predictive performance to sST2; how-
ever, hs-cTnT has the advantage of being widely available in the clinical setting. A multimarker
strategy has been used in other scenarios of HF patients, showing to improve the prognostic
performance of every single biomarker assessment. We analyzed the value of the biomarkers
combination in CCM patients, finding that the combination of NT-proBNP and sST2 or hs-
cTnT significantly increased the prognostic accuracy in predicting our CO.
The need for reliable serum biomarkers for predicting outcomes such as mortality and ther-
apeutic response in CCM has been assessed in multiple studies [9, 10, 17, 18]. Natriuretic pep-
tides are the most studied biomarker in HF associated with CCM [12]. However, few studies
have addressed the prognostic value of this and several other biomarkers in CCM. Moreira
et al. evaluated natriuretic peptides as mortality predictors at three years of follow-up in CCM
patients, finding that higher atrial natriuretic peptide (ANP) and BNP concentrations were sig-
nificantly associated with a higher risk of death/heart transplant [17]. Sherbuk et al. confirmed
Table 2. Prognostic value of the log-transformed biomarker levels in a continuous manner and using cut-off
points for the composite outcome in patients with CCM (n = 100).
Biomarker HR� Adjusted Model AUC
95% CI p-value
NT-proBNP 2.02 1.43–2.85 0.000 85.06
hs-cTnT 2.65 1.71–4.14 0.000 85.82
sST2 3.98 1.82–8.66 0.000 84.31
Galectin-3 2.41 0.91–6.32 0.075 83.55
Cys-C 8.17 1.51–44.29 0.015 83.46
NGAL 2.05 0.84–4.97 0.112 82.38
sST2 (>35 vs.�35) 3.62 1.49–8.78 0.004 84.68
hs-cTnT (>15 vs.�15) 3.24 1.26–8.33 0.014 83.51
Galectin-3 (>16.7 vs. �16.7) 1.65 0.68–4.04 0.265 82.70
NT-proBNP (>1000 vs. �1000) 3.57 0.93–13.68 0.063 82.66
Cys-C (>1.1 vs.�1.1) 1.48 0.52–4.18 0.451 81.29
NGAL (>96.5 vs.�96.5) 1.47 0.51–4.211 0.464 81.39
sST2 >35 + NT-proBNP >1000¥ 11.84 1.97–70.85 0.007 86.10
sST2 >35 + hs-cTnT >15¥ 4.01 1.66–9.66 0.002 85.20
NT-proBNP >1000 + hs-cTnT>15¥ 3.18 1.31–7.79 0.011 84.07
sST2 >35 + NT-proBNP >1000 + hs-cTnT >15¥ 11.25 1.94–65.14 0.007 85.75
�HR adjusted by age and left ventricular ejection fraction.
¥The HR is derived from comparing the group of patients with the levels of the biomarkers over the cut-off values vs.
those with the evaluated biomarkers below the selected cut-offs.
https://doi.org/10.1371/journal.pone.0258622.t002
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these results in a study that analyzed the prognostic value of BNP, NT-proBNP, creatine
kinase-myocardial band (CK-MB), troponin I, matrix metalloproteinase (MMP-2), MMP-9,
and tissue inhibitor of metalloproteinases (TIMP) 1 and 2 in a group of 50 T. cruzi-infected
Stage D Bolivian patients. In this study, higher baseline levels of BNP, NT-proBNP, CK-MB,
and MMP-2 were significantly associated with increased mortality at 14 months [14]. Interest-
ingly, in our study dichotomic Hs-cTnT had a similar prognostic value when compared to
NT-proBNP and Hs-cTnT combination, a finding that may improve the assessment of CCM
patients in low-resource settings, in which Hs-cTnT may be cheaper and more easily
performed.
To date, no study evaluating the prognostic value of hs-cTnT, Gal-3, NGAL, sST2, and Cys-
c in CCM has been reported, and our group recently reported the only study that has assessed
the role of these biomarkers in CD in a cross-sectional fashion [19]. However, these serum bio-
markers have already been studied in HF of other etiologies, showing promising results [20–
22]. In the present study, we found that higher concentrations of these biomarkers were associ-
ated with higher risk features, and in the case of all but NGAL and Galectin-3, they were all
associated with a higher risk for future cardiovascular events even after adjusting for age and
Fig 2. Bar graph and Kaplan Meier survival analyses for the composite outcome stratified by combined NT-proBNP and ST2 according to selected cut-off values.
https://doi.org/10.1371/journal.pone.0258622.g002
Fig 3. Bar graph and Kaplan Meier survival analyses for the composite outcome stratified by combined NT-proBNP and Hs-cTnT according to selected cut-off
values.
https://doi.org/10.1371/journal.pone.0258622.g003
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LVEF. Considered dichotomously in the manner a clinician might analyze biomarker results,
the biomarkers studied predicted a 3 to 11-fold increase in the risk of having any composite
outcome events. Given that CCM most often occurs in resource-constrained health care envi-
ronments, these results might help clinicians in decision making, including consideration for
transplantation evaluation.
Study limitations
Our study has some significant limitations, including the limited sample size and the lack of
inclusion of patients in the disease’s indeterminate form (positive for T. cruzi, with normal
ECG and echo), which could have provided insight into the role of cardiovascular biomarkers
in asymptomatic individuals. In this cohort, we report a mortality rate of 0.15 per 1000 person-
years at two years, which is significantly lower compared to previously reported event rates in
similar studies [15]. The reasons for this difference are not apparent but may be related to differ-
ences in the compliance with optimal pharmacological treatment schemes across populations,
implantable cardioverter defibrillator insertion rates, and follow-up by a specialized heart failure
clinic [15, 23, 24]. Furthermore, we could not assess the role of implantable cardioverter-defi-
brillator use in the results, as ICD shocks may have been a relevant part of the CO considering
the arrhythmogenic nature of CCM. Finally, the lack of repeated measures of the assessed bio-
markers precluded assessing potential variations of the patients’ clinical status during the fol-
low-up period, for example, after changes in medical therapy or lifestyle interventions.
Conclusion
Chronic Chagas cardiomyopathy manifests with high short-term morbidity, mortality, and
significant expenditure for the healthcare system. In our prospective cohort study, we found
Fig 4. Kaplan Meier survival analysis for the composite outcome stratified by combined NT-proBNP, Hs-cTnT
and sST2 according to selected cut-off values.
https://doi.org/10.1371/journal.pone.0258622.g004
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that four serum biomarkers (NT-proBNP, hs-cTnT, sST2, and Cys-C) were significantly asso-
ciated with a higher risk of the CO among patients with CCM. The combination of NT-
proBNP and sST2 or hs-cTnT provided the highest discrimination for major cardiovascular
outcomes primarily driven by death. Larger multi-center studies should validate these results
to identify certain biomarkers optimal for improving the prediction of adverse outcomes in
CCM and potentially developing a risk score that may improve targeted therapies in this high-
risk population.
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Writing – original draft: Sergio Alejandro Gómez-Ochoa, Oscar L. Rueda-Ochoa, Cristian
David Sosa-Vesga, James L. Januzzi, Rachel Marcus.
Writing – review & editing: Luis E. Echeverrı́a, Lyda Z. Rojas, Sergio Alejandro Gómez-
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